- Home
- AXIL vs KALA Comparison
AXIL vs KALA Comparison
Compare AXIL & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- KALA
- Stock Information
- Founded
- AXIL 2015
- KALA 2009
- Country
- AXIL United States
- KALA United States
- Employees
- AXIL N/A
- KALA N/A
- Industry
- AXIL Package Goods/Cosmetics
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- AXIL Consumer Discretionary
- KALA Health Care
- Exchange
- AXIL Nasdaq
- KALA Nasdaq
- Market Cap
- AXIL 36.5M
- KALA 26.2M
- IPO Year
- AXIL N/A
- KALA 2017
- Fundamental
- Price
- AXIL $5.02
- KALA $5.86
- Analyst Decision
- AXIL
- KALA Strong Buy
- Analyst Count
- AXIL 0
- KALA 3
- Target Price
- AXIL N/A
- KALA $14.00
- AVG Volume (30 Days)
- AXIL 12.5K
- KALA 118.3K
- Earning Date
- AXIL 08-14-2025
- KALA 08-05-2025
- Dividend Yield
- AXIL N/A
- KALA N/A
- EPS Growth
- AXIL 93.65
- KALA N/A
- EPS
- AXIL 0.29
- KALA N/A
- Revenue
- AXIL $27,007,463.00
- KALA N/A
- Revenue This Year
- AXIL N/A
- KALA N/A
- Revenue Next Year
- AXIL N/A
- KALA N/A
- P/E Ratio
- AXIL $17.48
- KALA N/A
- Revenue Growth
- AXIL N/A
- KALA N/A
- 52 Week Low
- AXIL $3.54
- KALA $2.92
- 52 Week High
- AXIL $10.75
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- AXIL 40.20
- KALA 60.68
- Support Level
- AXIL $4.84
- KALA $4.36
- Resistance Level
- AXIL $5.30
- KALA $7.00
- Average True Range (ATR)
- AXIL 0.40
- KALA 0.71
- MACD
- AXIL -0.01
- KALA 0.16
- Stochastic Oscillator
- AXIL 21.84
- KALA 63.97
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.